New combo aims to stall sarcomas in tough cases

NCT ID NCT05182164

Recruiting now Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two drugs, pembrolizumab and cabozantinib, together in people with advanced sarcomas (cancers of the soft tissue or bone) that have not responded to standard treatments. The goal is to see if the combination can stop or shrink tumors for at least 6 months. About 119 adults with specific sarcoma types will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma osteosarcoma sarcoma soft tissue sarcoma undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOFT TISSUE SARCOMA EWING SARCOMA OSTEOSARCOMA SOFT TISSUE SARCOMA ADULT UNDIFFERENTIATED PLEOMORPHIC SARCOMA

Contacts and locations

Locations

Centre Georges François Leclerc
RECRUITING

Dijon, 21079, France
Centre Leon Berard
NOT_YET_RECRUITING

Lyon, 69008, France
Centre Oscar Lambret
NOT_YET_RECRUITING

Lille, 59020, France
Hôpital La Timone
RECRUITING

Marseille, 13385, France
IUCT Oncopole
NOT_YET_RECRUITING

Toulouse, 31059, France
Institut Bergonie
RECRUITING

Bordeaux, 33076, France
Institut Curie
NOT_YET_RECRUITING

Paris, 75248, France
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France
Institut Paoli Calmettes
RECRUITING

Marseille, 13009, France
Institut de Cancérologie de l'Ouest - Site René Gauducheau
RECRUITING

Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.